Jiangsu Maiweikang

Jiangsu Maiweikang Biotechnology Co., Ltd. is a specialized molecular diagnostics company headquartered in the China Medical City of Taizhou, Jiangsu Province. Founded in 2015, the company focuses on the development, manufacturing, and sale of in vitro diagnostic (IVD) kits for oncology and precision medicine. Its core product line includes high-sensitivity mutation detection kits for biomarkers such as EGFR, KRAS, and BRAF, which are critical for determining patient eligibility for targeted cancer therapies. Maiweikang utilizes advanced molecular biology platforms, including ARMS-PCR and Next-Generation Sequencing (NGS), to provide clinicians with reliable diagnostic data. The company's solutions are primarily applied in the management of non-small cell lung cancer and colorectal cancer. By bridging the gap between genetic research and clinical application, Maiweikang aims to enhance the efficacy of personalized cancer treatments.